论文部分内容阅读
目的:探讨雾化吸入糖皮质激素治疗慢性阻塞性肺病急性加重期(AECOPD)的临床效果。方法:60例AECOPD患者随机分为治疗组和对照组,对照组给予抗感染、吸氧、化痰等常规治疗,治疗组在常规治疗的基础上给予糖皮质激素雾化吸入治疗,连续治疗14d后评价临床疗效,观察治疗前后两组患者的临床症状和肺功能改善情况。结果:治疗组临床疗效有效率为96.7%,高于对照组(80.0%),相比较有显著性差异(P<0.05);治疗组临床症状评分和呼吸困难评分与治疗前和对照组比较显著下降,相比较有显著性差异(P<0.05);治疗组FEV1、FEV水平与治疗前和对照组比较显著上升,肺功能改善显著,相比较有显著性差异(P<0.05)。结论:雾化吸入糖皮质激素治疗AECOPD疗效肯定,值得临床推广应用
Objective: To investigate the clinical effect of inhaled glucocorticoid on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Sixty AECOPD patients were randomly divided into treatment group and control group. The control group was given anti-infection, oxygen, phlegm and other conventional treatment. The treatment group was given glucocorticoid inhalation therapy on the basis of routine treatment. After continuous treatment for 14 days After the evaluation of clinical efficacy, observed before and after treatment in both groups of patients with clinical symptoms and pulmonary function improvement. Results: The effective rate of clinical curative effect in the treatment group was 96.7%, which was higher than that in the control group (80.0%) (P <0.05). The clinical symptom scores and dyspnea scores of the treatment group were significantly higher than those before treatment and the control group (P <0.05). The levels of FEV1 and FEV in the treatment group increased significantly compared with the control group before treatment and the pulmonary function improved significantly (P <0.05). Conclusion: AECOPD with inhaled glucocorticoid is effective and worthy of clinical application